-
公开(公告)号：EP2571353A1
公开(公告)日：2013-03-27
申请号：EP10851903.4
申请日：2010-11-19
申请人： AbbVie Inc. , Abbott GmbH & Co. KG
发明人： AKRITOPOULOU-ZANZE, Irini , BRAJE, Wilfried , DJURIC, Stevan W. , WILSON, Noel S. , TURNER, Sean C. , KRUGER, Albert W. , RELO, Ana-Lucia , SHEKHAR, Shashank , WELCH, Dennie S. , ZHAO, Hongyu , GANDARILLA, Jorge , GASIECKI, Alan F. , LI, Huanqiu , THOMPSON, Christina M. , ZHANG, Min
CPC分类号： C07D487/04 , C07D491/04 , C07D495/04 , C07D513/04
摘要： The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[c]pyrrole, and octahydrocyclohepta[c]pyrrole derivatives of formula (I) wherein R1, R2, R3, R4, R5, A, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, processes for making such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.
摘要翻译： 本申请涉及芳基 - 和杂芳基稠合的decahydropyrroloazepine，octahydrooxepinopyrrole，octahydropyrrolothiazepine氧化钛，decahydrocyclohepta并[c]吡咯，和三烯并[c]吡咯的式（I）worin R1，R2，R3，R4，R5，A，Y1的衍生物 ，Y2，Y3和如说明书中所定义。 因此，本申请涉及组合物，包含测试的化合物，用于鉴定受试化合物处理用于制造检验化合物，以及一种使用测试化合物和组合物的疾病病症的方法，与方法。
-
公开(公告)号：EP2571353B1
公开(公告)日：2017-08-09
申请号：EP10851903.4
申请日：2010-11-19
发明人： AKRITOPOULOU-ZANZE, Irini , BRAJE, Wilfried , DJURIC, Stevan W. , WILSON, Noel S. , TURNER, Sean C. , KRUGER, Albert W. , RELO, Ana-Lucia , SHEKHAR, Shashank , WELCH, Dennie S. , ZHAO, Hongyu , GANDARILLA, Jorge , GASIECKI, Alan F. , LI, Huanqiu , THOMPSON, Christina M. , ZHANG, Min
IPC分类号： C07D487/04 , C07D491/04 , C07D495/04 , C07D513/04
CPC分类号： C07D487/04 , C07D491/04 , C07D495/04 , C07D513/04
-
搜索结果
2 条记录 (耗时 0.02 秒)
